Ask for high quality link  by putting your email below

Ask for high quality link by putting your email below

Please, double check your email!

Genotoxicity potential assessment of pharmaceuticals is mandatory for registration. In addition to the standard in vitro/ in vivo test battery, other assays can be of interest because of their high throughput in the drug discovery stage but also for mechanistic understanding.

Different other assays can be performed to detect DNA damage, such as γH2AX and the single cell gel electrophoresis (or comet assay).


The γH2AX assay was suggested as a new in vitro assay for detecting genotoxic properties of chemicals. The phosphorylation of γH2AX has been demonstrated to be a sensitive marker for a wide range of DNA damage. In this study, primary human keratinocytes were evaluated to provide a more relevant testing system for genotoxicity assessment in the skin for topical dermatological/cosmetic substances. Primary human keratinocytes were compared to the well known HepG2 cell line for which data have already been published.

The comet assay is a sensitive, well established technique for quantifying DNA damage in eukaryotic cells and enabling the detection of a wide range of DNA damaging agents. The assay can be adapted in a 96 wells format allowing higher throughput.

The high content imaging (HCI) analysis applied to genotoxicity assays is a valuable tool allowing higher throughput and multi-parametric analysis in order to improve predictability of these assays.

View and download on Slideshare (low quality) :

Grégory MAUBON

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.

1 Comment

ESTIV2016 : a feedback | HCS-pharma · November 4, 2016 at 2:02 pm

[…] Among all the very good and informative presentations, we were really glad to attend the ones done by collaborators HCS Pharma work with. Also, a poster, showing the results obtained from a collaborative work between HCS Pharma and Galderma, has been presented and discussed with visitors interested in genotoxicity assessment. This poster, about assessment of primary DNA damages with gammaH2AX and comet assays on primary huma… […]

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.